Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression
Annual Review of Medicine November 11, 2024 Elizabeth Richardson, Riah Patterson, Samantha Meltzer-Brody et al. 33 citations
Depressive disorders present an enormous global public health burden. A notable treatment gap exists between the prevalence of depression and our ability to provide rapid-acting, effective treatment that achieves remission. Brexanolone and zuranolone, the first US Food and Drug Administration–approved drugs for postpartum depression, signify a critical advancement in addressing the unmet needs...
DOI: 10.1146/annurev-med-050423-095712 (opens in new tab)
Psilocybin
Treatment-resistant depression
Depression treatment
Postpartum depression therapy
+7